Lykan Bioscience, a manufacturer specializing in cell-based therapies, announced plans to expand its facility in Hopkinton by 1,700 square feet.
The expansion would add seven new manufacturing suites, which adhere to the U.S. Food & Drug Administration’s regulatory guidelines for U.S. clinical and commercial production, according to the Nov. 9 announcement.
The 1,700-square-foot laboratory will house industry advanced cell therapy processing and analytical technologies, per the release.
Ultimately, the addition would increase Lykan Bioscience’s clinical and commercial manufacturing capacity by 90%.
According to a company statement, the laboratory expansion is expected to be operational for customer projects by the end of the year.
